Tdspharm Co., Ltd. (KOSDAQ:464280)
South Korea · Delayed Price · Currency is KRW 6,440.00
-40.00 (-0.62%)
Jun 10, 2026, 3:30 PM KST
Tdspharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 30,411 | 27,621 | 27,519 | 30,049 | 25,588 | 19,820 |
Other Revenue | -0 | -0 | -0 | - | -0 | -0 |
| 30,411 | 27,621 | 27,519 | 30,049 | 25,588 | 19,820 | |
Revenue Growth (YoY) | 19.57% | 0.37% | -8.42% | 17.43% | 29.11% | 9.97% |
Cost of Revenue | 21,824 | 20,131 | 19,818 | 22,140 | 19,454 | 15,864 |
Gross Profit | 8,587 | 7,489 | 7,701 | 7,910 | 6,134 | 3,956 |
Selling, General & Admin | 2,710 | 2,732 | 3,015 | 2,236 | 1,683 | 1,168 |
Research & Development | 653.96 | 665.91 | 622.5 | 441.2 | 478.84 | 356.11 |
Amortization of Goodwill & Intangibles | 22.93 | 33.19 | 66.44 | 16.49 | - | 0.62 |
Other Operating Expenses | 70.96 | 74.99 | 46.65 | 51.14 | 45.79 | 36.2 |
Operating Expenses | 3,666 | 3,724 | 3,972 | 2,893 | 2,353 | 1,641 |
Operating Income | 4,920 | 3,765 | 3,730 | 5,016 | 3,781 | 2,314 |
Interest Expense | -249.59 | -222.78 | -267.69 | -301.46 | -220.65 | -129.58 |
Interest & Investment Income | 800.47 | 888.97 | 846.66 | 521.07 | 216.96 | 53.02 |
Currency Exchange Gain (Loss) | -8.23 | 0.01 | -4.2 | -1.69 | -0.03 | 3.63 |
Other Non Operating Income (Expenses) | 30.51 | 23.76 | -4 | 254.57 | 115.14 | 165.98 |
EBT Excluding Unusual Items | 5,494 | 4,455 | 4,300 | 5,489 | 3,892 | 2,407 |
Gain (Loss) on Sale of Assets | 517.52 | 517.52 | -88.76 | 0.2 | 6.24 | 11.14 |
Asset Writedown | - | - | - | - | -52.24 | - |
Pretax Income | 6,011 | 4,973 | 4,212 | 5,489 | 3,846 | 2,419 |
Income Tax Expense | 956.62 | 698.14 | 493.87 | 801.14 | 390.36 | 355.75 |
Net Income | 5,055 | 4,275 | 3,718 | 4,688 | 3,456 | 2,063 |
Net Income to Common | 5,055 | 4,275 | 3,718 | 4,688 | 3,456 | 2,063 |
Net Income Growth | 54.33% | 14.97% | -20.70% | 35.66% | 67.52% | 52.66% |
Shares Outstanding (Basic) | 5 | 5 | 5 | 4 | 4 | 0 |
Shares Outstanding (Diluted) | 5 | 5 | 5 | 4 | 4 | 0 |
Shares Change (YoY) | 7.95% | 14.22% | 8.74% | -0.07% | 4511.34% | -7.60% |
EPS (Basic) | 956.97 | 808.27 | 803.00 | 1101.00 | 811.00 | 22325.01 |
EPS (Diluted) | 956.97 | 808.27 | 803.00 | 1101.00 | 811.00 | 22325.01 |
EPS Growth | 42.96% | 0.66% | -27.07% | 35.76% | -96.37% | 65.21% |
Free Cash Flow | -8,298 | -9,104 | 3,213 | 3,080 | 2,317 | 3,479 |
Free Cash Flow Per Share | -1571.04 | -1721.47 | 694.06 | 723.32 | 543.79 | 37650.19 |
Gross Margin | 28.24% | 27.12% | 27.98% | 26.32% | 23.97% | 19.96% |
Operating Margin | 16.18% | 13.63% | 13.55% | 16.69% | 14.77% | 11.68% |
Profit Margin | 16.62% | 15.48% | 13.51% | 15.60% | 13.51% | 10.41% |
Free Cash Flow Margin | -27.29% | -32.96% | 11.68% | 10.25% | 9.05% | 17.55% |
EBITDA | 5,629 | 4,465 | 4,398 | 6,038 | 5,047 | 3,545 |
EBITDA Margin | 18.51% | 16.16% | 15.98% | 20.09% | 19.72% | 17.89% |
D&A For EBITDA | 708.99 | 699.57 | 668.59 | 1,022 | 1,266 | 1,230 |
EBIT | 4,920 | 3,765 | 3,730 | 5,016 | 3,781 | 2,314 |
EBIT Margin | 16.18% | 13.63% | 13.55% | 16.69% | 14.77% | 11.68% |
Effective Tax Rate | 15.91% | 14.04% | 11.73% | 14.59% | 10.15% | 14.71% |